Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Palatin Technologies Inc (PTN)
:PTN
RESEARCH TOOLSreports
Holding PTN?
Track your performance easily
Earnings Data
Report Date
Feb 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.42Last Year’s EPS
-0.56Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2018
|% Change Since: -10.92%
|Next Earnings Date:Sep 13, 2018
Earnings Call Sentiment|Neutral
The earnings call highlighted strategic shifts towards obesity programs, with promising enrollment and expected results in several studies. However, the financials showed challenges with increased net loss and decreased cash position due to the elimination of Vyleesi sales.Company Guidance
During Palatin's First Quarter Fiscal Year 2025 earnings call, the company outlined several key financial metrics and strategic directions. Palatin reported no product sales for the quarter ending September 30, 2024, following the sale of Vyleesi's worldwide rights. Operating expenses decreased to $7.8 million from $8.2 million in the same period last year, while the net cash used in operations rose to $7 million compared to $5.9 million in 2023. The net loss for the quarter was $7.8 million, up from $5.2 million the previous year. As of September 30, 2024, cash and cash equivalents were $2.4 million, a decrease from $9.5 million in June 2024. Looking forward, the company is focusing on its MCR-4 obesity assets, anticipating top-line results from their Phase II obesity study in the first quarter of 2025. Palatin is also exploring strategic options for its non-obesity programs, noting significant interest in their ocular and ulcerative colitis programs from potential partners.Strategic Focus on Obesity Programs
Palatin is focusing its future investment and activities on its core programs in obesity, specifically the MCR4 obesity assets. The company believes the obesity market will have a market value greater than $100 billion per year.
BMT-801 Study Fully Enrolled
Palatin's Phase II study, BMT-801, evaluating bremelanotide with tirzepatide in obesity, is fully enrolled with 115 patients. Due to high demand and rapid enrollment, the study size increased, with top line results expected in Q1 2025.
Potential Out-Licensing Opportunities
Palatin is exploring strategic options for its non-obesity programs, with significant interest in its Phase III dry eye disease program and early-stage glaucoma and retina development programs from multiple parties.
---
PTN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
PTN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 14, 2024 | $1.19 | $1.07 | -10.08% |
| Oct 01, 2024 | $0.89 | $0.88 | -1.12% |
| May 15, 2024 | $2.41 | $2.07 | -14.11% |
| Feb 15, 2024 | $4.14 | $3.15 | -23.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Palatin Technologies Inc (PTN) report earnings?
Palatin Technologies Inc (PTN) is schdueled to report earning on Feb 18, 2025, TBA Not Confirmed.
What is Palatin Technologies Inc (PTN) earnings time?
Palatin Technologies Inc (PTN) earnings time is at Feb 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PTN EPS forecast?
PTN EPS forecast for the fiscal quarter 2025 (Q2) is -0.42.
---